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Abstract
Duchenne Muscular Dystrophy (DMD) is a complex process involving multiple pathways downstream of the primary genetic
insult leading to fatal muscle degeneration. Aging muscle is a multifactorial neuromuscular process characterized by
impaired muscle regeneration leading to progressive atrophy. We hypothesized that these chronic atrophying situations
may share specific myogenic adaptative responses at transcriptional level according to tissue remodeling. Muscle biopsies
from four young DMD and four AGED subjects were referred to a group of seven muscle biopsies from young subjects
without any neuromuscular disorder and explored through a dedicated expression microarray. We identified 528
differentially expressed genes (out of 2,745 analyzed), of which 328 could be validated by an exhaustive meta-analysis of
public microarray datasets referring to DMD and Aging in skeletal muscle. Among the 328 validated co-expressed genes,
50% had the same expression profile in both groups and corresponded to immune/fibrosis responses and mitochondrial
metabolism. Generalizing these observed meta-signatures with large compendia of public datasets reinforced our results as
they could be also identified in other pathological processes and in diverse physiological conditions. Focusing on the
common gene signatures in these two atrophying conditions, we observed enrichment in motifs for candidate transcription
factors that may coordinate either the immune/fibrosis responses (ETS1, IRF1, NF1) or the mitochondrial metabolism
(ESRRA). Deregulation in their expression could be responsible, at least in part, for the same transcriptome changes
initiating the chronic muscle atrophy. This study suggests that distinct pathophysiological processes may share common
gene responses and pathways related to specific transcription factors.
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Introduction
Skeletal muscles comprise 40–50% of the total adult human
body mass and are responsible for a number of functions including
force generation, movement and body support. Skeletal muscle size
depends upon a dynamic balance between hypertrophic and
atrophic processes. The maintenance of muscle fiber size is tightly
regulated by intracellular signaling networks that determine the
balance between overall rates of protein synthesis and degradation
[1]. While muscle hypertrophy occurs with physical exercise [2],
there are a number of physiological or pathological conditions in
which a loss of skeletal muscle mass occurs [3]. They include
Duchenne muscular dystrophy (DMD) which is characterized by
rapidly progressive muscle degeneration primary caused by lack of
dystrophin, and sarcopenia which specifically refers to the irreversible
decline of skeletal muscle mass, strength, and function with age [4].
Dystrophin is a large protein located at the intracellular region
of the sarcolemma and participates to cellular adhesion by
connecting the cytoskeleton to the extracellular matrix [5]. This
supported the mechanical strength of the sarcolemma against
muscle contraction-induced tension [6]. It was generally admitted
that in muscle lacking dystrophin, this connection was weakened
and sarcolemma was exposed to high tension. That led to partial
disruptions of sarcolemma and influx of extracellular Ca
2+ that
activated the calcium-dependent degradative pathway, myofibril
disruption and muscle necrosis or apoptosis [7] along with
incomplete regeneration cycles, proliferation of connective and
adipose tissue, infiltration of immune cells and reduced number of
slow oxidative muscle fibers [8].
Sarcopenia is associated with a preferential alteration in the
number and size of type II muscle fibers. Many neuro-muscular
and systemic factors have been implicated in the pathogenesis of
PLoS ONE | www.plosone.org 1 November 2011 | Volume 6 | Issue 11 | e26952sarcopenia including loss of type II alpha motor neurons, decline
in muscle fiber contractility, deficient satellite cell recruitment,
enhanced oxidative stress, mitochondrial dysfunction, loss of
growth and sex hormone production, activation of proteolytic
pathway, dysregulation of catabolic cytokines [9]. At the single
muscle fiber level, sarcopenia was associated to hallmarks of
morphological apoptosis, decline in protein synthesis increased
DNA, protein and lipid oxidation, accumulation of mitochondrial
abnormalities and calcium dyshomeostasis [10–14].
Taken together, these data suggest that common remodeling
process occurred in both pathological and aging atrophying
conditions and that it may be related to transcriptional alterations
affecting numerous molecular pathways and biological functions,
modifying tissue and morphological characteristics of the muscle.
We hypothesized that common gene signatures may arise in the
DMD and aged human skeletal muscle. One tool that might define
a molecular portrait of muscle in these conditions is gene expression
profiling using microarrays [15]. This method has been successfully
applied in the field of muscle research, particularly for several
human diseases [16,17]. We thus performed gene expression
profiling in skeletal muscle biopsies from DMD and aged patients.
The results, meta-analyzed in the context of available public
microarray data, enabled us to highlight common molecular
signatures. Here we demonstrated that DMD and AGE share
common transcriptional changes related to the tissue remodeling
occurringinthe atrophying skeletalmuscle. Moreover, theobserved
patterns could be regulated by common transcription factors (TFs)
to be identified.
Results
In laboratory study
Hierarchical clustering of microarray data. RNA
samples from 4 DMD and 4 AGE skeletal muscle tissues were
analyzed by hybridization against control samples. This
hybridization was done on microarrays containing quadruplicate
50-mer oligonucleotides corresponding to 3,588 muscle relevant
genes. Two hybridizations were performed for each subject. Thus,
eight values per gene were obtained for each subject. These
stringent conditions conferred powerful significance to our results.
After the filtering procedure and the consolidation step, valid
expression values (i.e relevant measure of the spot signal above the
background) were obtained for 2,745 genes in all subjects.
Clustering was performed using the median of the four values
per microarray of these 2,745 genes for DMD and AGE subjects
(Figure 1.A). As expected, duplicate microarrays clustered
together and two distinctive clusters appeared: one consisting of
DMD patients and one of AGE subjects.Two tests were then
performed: DMD vs CONTROL and AGE vs CONTROL. After
statistical analyses (SAM and LIMMA), 528 genes were found to
be differentially expressed (p,0.01). Among this list, 3 distinct sets
of differentially expressed genes (DEGs) were identified: DMD set
(DEGs in DMD but not in aging muscle), AGE set (DEGs in aging
muscle but not in DMD muscle), and DMD-AGE set (genes
commonly modified in the two situations and corresponding to the
overlap between the two tests) (Figure 1.B). For each set we found
up and down regulatedgenes asdescribed inFigure1.C. DMDset
was composed of 363 genes and AGE set of 329 genes. Majority of
genes found in DMD+AGE set were consistently deregulated (66
up-regulated and 88 down regulated in both situations), 10 were
inconsistently deregulated (i.e. deregulated in the opposite sense).
Complete gene lists are available in Table S1 (part 1).
Quantitative RT-PCR validation. Differential expression of
10 genes was confirmed by quantitative RT-PCR analysis of 3 of
the 4 DMD and 3 of the 4 AGE subjects’ biopsies. Ten genes
representing different levels of up- or down-regulation in both
conditions were tested and HERZ was used as internal control.
Figure 2 shows an example of the good correlation between RT-
PCR and microarray results for one DMD patient (Pearson’s
correlation, r=0.88). Identical correlations were observed for all
patients (data not shown) supporting technical validation of the
microarray results.
Orientated Validation: data processing from DMD and
AGE public studies
To validate our microarray results, we performed a meta-
analysis on the genes we found differentially expressed in at least
one of the two conditions (DMD or AGE) (Figure 3). We
validated 233 common genes across 6 distinct DMD data sets, and
178 genes across 6 distinct AGE data sets. Those DMD and AGE
data were integrated to our results and we identified 328 common
relevant genes (Figure 3). According to their significant status of
expression (+: over-expression compared to the control group; 2:
under-expression; 0: no change), 9 distinct meta-clusters of DEGs
were defined. Four of them corresponded to genes specifically
modified in DMD or in AGE. Two of them integrated differentially
expressed genes in the two conditions that were anti-correlated
(DMD+ AGE2; DMD2 AGE+). The last three clusters included
DMD and AGE correlated genes. Among all of those cross-
validated genes, only 30 had a substantial sex-biased expression: 16
were over expressed in male muscle and 14 in female.
Blind validation: data processing from a wide panel of
public studies
We interrogated large compendia of re-analyzed public
microarray datasets to assess the reliability of our results. We
identified common transcriptional studies using different meta-
analysis approaches (Figure 4). These analyses enabled us to re-
validate, the meta-clusters in term of coexpression (Figure 4.A),
significant fold changes (Figure 4.B) and gene signatures
similarities (Figure 4.C). This validation was done with a high
level of confidence (p-value,0.05), across a wide range of
conditions (from normal to pathological), in various species. We
identified for each of the meta-gene (obtained from our orientated
meta-analysis) recurrent co-expression neighbors across multiple
datasets (Figure 4.A). The results are exemplified for the meta-
genes over-expressed in DMD, and DMD+AGE muscle. We
found a clear and specific association with genes implicated in
immune response and fibrosis. We looked for datasets sharing our
differentially expressed meta-genes (Figure 4.B). These studies
mainly involved up-regulated genes in invasion processes: immune
response and regulation, cell adhesion to ECM components and
ability to remodeling the extra-cellular space (See Table S2 for
some particular examples).
In the third strategy (Figure 4.C), the composition of several
gene expression signatures was compared to our meta-clusters.
The meta-cluster of genes over-expressed in DMD and DMD+
AGE were similar to gene signatures involved in the ‘ECM’ and
the ‘immune response’. Genes under-expressed both in DMD and
AGE group (DMD2 AGE2) shared high degree of similarity with
those playing a role in mitochondrial function. Similarities
between gene signatures involved in cell cycle and our meta-
genes specifically up-regulated in AGE or down-regulated in
DMD (DMD2 AGE+, DMD2 AGE0, DMD2 AGE2) were
found. Genes specifically down regulated in AGE muscle (DMD0
AGE2) strongly resembled gene signatures implicated in the
synaptic and nerve transmission.
DNA Chips in Atrophying Skeletal Muscle
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We searched for GO terms significantly biased (either enriched
or depleted) in the different meta-clusters compared to the overall
GO terms found (Figure 5.A). Functional annotation corrobo-
rates results inferred from the blinded meta-analyses (see Figure
S1 available on line). Remarkably, invariant genes (DMD0 AGE0)
Figure 1. In lab Gene expression profiling in DMD and AGED skeletal muscle. A- Two-way hierarchical clustering of expression values
measured in our lab from the 8 subjects (4 DMD and 4 AGED) on the 2,745 validated genes (i.e genes having reliable expression values). Each row
represents a gene, and each column represents a sample. The dendrogram represents correlation distances between expression levels of genes
(horizontally) or samples (vertically). Blue and purple color code is associated to DMD and AGED samples, respectively. Each cell in the matrix
corresponds to an expression level, with red for over-expression, green for under-expression, and black for gene expression close to the median (see
the color scale). B- Three distinct sets of differentially expressed genes (DEGs) have been identified from the 528 significant genes extracted by SAM
and LIMMA analysis: (1) DMD set consists in 199 differential genes expression profiles only in DMD (up and down regulated genes) (2) AGED set
consists in 165 differential gene expression profiles only in aged (up and down regulated genes). (3) DMD+AGED set consists in 164 common gene
expression profiles (up and down regulated genes). C- Number of genes associated to each set according to their expression level. Pink values: genes
differentially regulated in AGED set only, blue values: genes differentially regulated in DMD set only, purple values: genes differentially regulated in
DMD+AGED set only. In DMD set, 105 genes were over expressed and 94 under expressed. In AGED set, 79 genes were over expressed and 86 under
expressed. In DMD+AGED set, 66 up regulated and 88 down regulated genes were consistently deregulated, 10 (7 DMD2 AGED+; 3 DMD+ AGED2)
genes were deregulated in the opposite sense.
doi:10.1371/journal.pone.0026952.g001
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‘ion transport’. Most of these GO terms were even under-
represented in up-regulated genes (DMD+ and AGE+). A ‘fibrosis’
and ‘lytic vacuole’ scheme was specifically associated with genes
over-expressed in DMD muscle (DMD+), including those
common with AGE (DMD+ AGE+). Many of these GO terms
were under-represented among down-regulated genes in DMD
muscle. In this last group (DMD2), ‘translation’ with ‘mitochon-
drion’ and ‘energy’ processes were found to be enriched and
shared with the group of down regulated genes in AGE. Finally,
while GO terms involved in ‘primary metabolism’ and ‘transcrip-
tion’ were specifically enriched in DMD down or AGE up
regulated genes, a specific over-representation of genes involved in
‘‘neurogenesis’’ and ‘‘cell death’’ was detected in down-regulated
genes in AGE process.
Benefiting from the results of the orientated meta-analysis, we
also searched for transcription factors (TF) differentially expressed
in at least DMD or AGE. Enriched binding sites of 14 over
expressed Transcription factors were found in the promoter of
genes identified in at least one of our meta-cluster (Figures 5.B
and 5.C)
Discussion
Identifying robust meta-signatures of pathophysiological
muscle
Progressive pathophysiology is a complex process involving
many pathways downstream of the primary molecular insult.
Microarray analyses provide comprehensive quantitative assays for
transcripts and have been broadly applied to assess alterations of
gene expression in diseases including neuromuscular disorders
[16,17]. In this study, we found 528 differentially expressed genes
in at least DMD or AGE group comparing to a reference group of
young and healthy subjects. Expression of 10 of those genes was
checked by quantitative RT-PCR analysis for 3 new subjects in
each DMD and AGE group. This approach has proved to be
successful to validate microarray data [15]. However, microarrays
are extremely sensitive to noise from experimental variables as
sample size [18]. This, combined with improper analysis or
validation, may leave some microarray-based studies to results that
are not robust [19–22]. Cross-validation studies (meta-analysis)
needs to be assessed across platforms and species to validate gene
changes that would often be difficult to distinguish in single
datasets [23–25]. Moreover in skeletal muscle, important varia-
tions in gene expression have been described considering sex type
and muscle allotypes among disease status [26].
We have performed a re-analysis and meta-analysis of 12
publicly available microarray datasets related to DMD or AGE
studies to comfort our initial data. The results enabled us to cross-
validate 328 gene expression profiles in at least one of the two
DMD/AGE examined situations. We reinforced the molecular
signature of muscle atrophy [27] by identifying similar deregula-
tions in various physiological situations (co-expression neighbors,
differential fold changes and gene signatures). While the meta-
analyzed public studies included limb muscles (most often
quadriceps femoris), our study explored fascia lata tensor and
paravertebral muscles. Thus cross-validated gene expressions we
proposed were likely to be independent from a muscle allotype
effect. According to their expression status in the two situations,
the cross-validated genes could be classified into 9 distinct gene
signatures (or meta-clusters). Among these genes, we could only
identify 30 genes (,9% of the cross-validated genes) having a
substantial sex-biased expression. However, in the 12 studies
included in the meta-analysis, AGING and DMD effects were
studied by comparison with a CONTROL population constituted
of a mix of male and female samples (global proportion ,60%
male and 40% female). These comparisons may thus favor a real
pathological effect (DMD or AGING) on the observed gene
Figure 2. Independent verification of microarray results by quantitative RT-PCR for a group of selected genes in a DMD patient.
Scatterplot illustrating the good concordance for 10 gene expression values measured by RT-PCR (y axis) and Microarray (x axis) in one of the DMD
samples. Each spot represents mean expression value measured for one gene either by RT-PCR (n=3) or by microarray experiment. The diagonal line
denotes the identity between RT-PCR and microarray expression values. Measured genes are listed in legend. RT PCR expression values are well
correlated with microarray expression values (Pearson’s correlation r=0.88).
doi:10.1371/journal.pone.0026952.g002
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sion in male muscle. Nine of the 16 genes were in fact down
regulated in DMD and 8 of these 9 genes were also commonly
down regulated in AGING. Despite this tendency, we argue
that observed variations are mainly due to the physiological
status of the muscle rather than sex influence. Sex may only
influence the expression of a minor part of them (,9%) in an
additive tone.
Figure 3. Meta-clusters specifically extracted from independent DMD and AGED public studies. Individualization of 10 metaclusters by
two-way hierarchical clustering of expression values across 6 DMD and 6 AGED public microarray studies. Each row represents a gene, and each
column represents a subject found in either DMD or AGED studies. Blue and purple color code shows DMD and AGED samples respectively. Each cell
in the matrix corresponds to an expression level, with red for over-expression, green for under-expression, and black for gene expression close to the
median (see the color scale). We identified genes modified either in at least DMD or AGED, commonly modified in both situations or not modified.
Genes cross-validated either in DMD studies either in Aging studies are showed in the center of the matrix with blue and purple pixels respectively.
Genes having significant sex biased expression are indicated with pixels (pink for higher expression in female muscle; light blue for higher expression
in male muscle) on the right of the matrix.
doi:10.1371/journal.pone.0026952.g003
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related and that tissue remodeling borrowed common pathways in
DMD and AGE muscle. Indeed, two independent pioneering
works identified a subset of genes that were commonly up- or
down-regulated [28,29]. Since all the diseases used for the
experiments of microarrays (i.e., diabetes, cancer cachexia,
chronic renal failure, fasting, and denervation) had muscle atrophy
in common, the up or down genes were believed to regulate the
loss of muscle components and were called ‘atrophy-related genes’
or ‘atrogenes’ [30]. Integration of gene expression profiles from
several studies enabled us to highlight genes that were consistently
over- or underexpressed in the two situations (DMD+ AGE+ and
DMD2 AGE2), thus representing meta-signatures of atrophying
muscle.
Common Gene signatures to DMD and AGE
Different causes of skeletal muscle atrophy could share a
common program of changes in gene expression [31]. In our
study, a group of genes involved in mitochondrial function and
protein synthesis shared reduced mRNA levels in skeletal muscle
from DMD and AGE groups (DMD2 AGED2). Calcium
dyshomeostasis, increased reactive oxygen species and mitochon-
drial dysfunction could play a key role in the process of the muscle
fiber degeneration by activating specific pathways commonly in
these two conditions. In sarcopenia, aged skeletal muscle contains
a large number of muscle fibers with segmental cytochrome c
oxidase deficiency and mitochondrial proliferation indicative of
mitochondrial metabolism dysfunction [32]. Clonal expansion of
mitochondrial DNA (mtDNA) mutations causes these focal muscle
Figure 4. Blind validation: Meta-analysis across a wide panel of public studies. A- Meta-clusters of co-expressed genes: hierarchical
clustering was applied to genes commonly extracted from our DMD/AGED meta-clusters in one hand (column) and 1,471 Gemma microarray data
sets on the other hand (line). Each cell of the matrix corresponds to the number of data sets were a gene is found significantly co-expressed to the
other. Light blue is attributed to high number of co-expressed genes and black to small number co-expressed genes. Functional annotation of highly
co-expressed gene clusters was performed (right hand). Genes associated to immune response and fibrosis were found to be co-expressed in our
DMD/AGED meta-clusters and a high number of Gemma data sets. B- Meta-clusters of data sets having similar significant fold-changes: hierarchical
clustering was applied to fold changes values extracted from our DMD/AGED meta-cluster in one hand (y axis) and 1,515 data sets extracted from
GeneChaser on the other hand (x axis). Each point of the x;y matrix corresponds a significant fold change value. Each fold change value is associated
to a rainbow color palette: fold change values upper than 1 are with hot colors and fold values lower than 1 are with cold colors. z axis corresponds to
probability associated to this fold-change to be true. The arrow delimits a cluster of studies associated to invasion processes where relevant similar
fold changes are observed. C- Top panel: heat map presenting overlapping similar signatures: gene composition of our 10 DMD/AGE meta-clusters
(=signatures) (horizontally), is compared to ,20,000 public transcriptional signatures (vertically). Those 20,000 signatures were extracted from
,1,500 microarray dataset using TBrowser. Each cell corresponds to a percentage of similarity in gene composition between each gene list. A color
code is attributed to each cell: red for good percentage of similarity and purple for bad values. For each meta-cluster, the 50 top overlapping clusters
from the database were retained. Bottom panel: horizontal hierarchical clustering of best hit public signatures (columns) on the basis of their
enrichment p-value found in Gene Ontology (row). A color code is attributed to each p-value (cell): yellow,black,blue. Some public signatures
extracted from comparison to our DMD/AGE signatures all gather in same GO annotated functions: mitochondrion, cell cycle, extra cellular matrix,
immune response, and nerve transmission.
doi:10.1371/journal.pone.0026952.g004
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in human aged skeletal muscle and was co-localized with
abnormal mitochondrial proliferation [34]. Thus, mitochondrial
dysfunction, apoptosis and muscle fiber atrophy was observed in
skeletal muscle of mtDNA mutator mice [35]. This could
corroborate a link between mitochondria decline and protein
synthesis decline observed in our study for the age group. Down-
regulation of these genes may thus indicate a ‘metabolic crisis’
reflected by the chronic decline in muscle function and
homeostasis. Indeed, several metabolic adaptations occur in
atrophying muscles and interestingly, in many forms of muscle
wasting. And expression of a variety of genes involved in glycolysis
and oxidative phosphorylation are also coordinately suppressed
[31].
Genes over-expressed in the two conditions (DMD+ AGED+)
belonged to the cell adhesion/extracellular matrix family, and
those encoding components of the immune response. Those effects
could be observed in other pathologies (e.g. spastic paraplegia) but
also in various tissues including muscle as an effect of AGE.
Recently, we demonstrated that in advanced heart failure, up and
down-regulated genes in the deteriorating samples involved
proteins of the extracellular matrix and mitochondrion, respec-
tively [36]. The extracellular matrix molecules are critical for
creating the cellular environment required during muscle
development and morphogenesis and muscle regeneration is a
highly efficient and reproducible process [37]. In senescent and
DMD muscles, tissue fibrosis and disruption of regenerative
potential are observed. This results in further perturbation of
skeletal muscle and activated immune cell infiltration [38–40].
While in DMD inflammation and fibrosis is an important
characteristic that for some researcher is the main causes of the
muscle loss, inflammation in skeletal muscle aging has long been a
debated point. There is a growing body of evidence suggesting that
sarcopenia is a smoldering inflammatory state driven by cytokines
and oxidative stress since elevated levels of interleukin-6 and C-
reactive protein are often detected (see ‘‘Inflammation and
AGING’’ in Data S1). In our study, 33% of the genes (25% of
the total) that could be linked to an immune/defence response (e.g.
IRF1, ETS1, STAT6, IL4R,…) as determined by database
searches were found in various published inflammatory signatures
(see part 2 of Table S1 for a description of the Immune related
genes), including the one occurring in the aging skeletal muscle
Figure 5. Meta-analysis of microarrays coupled with bioinformatics resources. A- Functional Annotation: GO term enriched subgroups
(Line) of each of our DMD/AGE meta-cluster (columns) were defined via GoMiner. Significant enrichment or impoverishment in GO terms (at 5% risk)
was shown respectively with red and green colors. The intensity of the color is directly proportional to the enrichment score. Each GO term enriched
subgroup was clusterized together on the basis of the generic function they belong to. Six main function were identified, each contributing
significant information to the overall interpretation of results. B- Transcription factors associated with DMD/AGE meta-clusters. Left panel: significant
enrichment values (cells) in transcription factor binding sites (rows) were attributed to each of our meta-cluster (column) mining transcription factor
(TF) data of MSignDB from GSEA. Red and green colors were respectively attributed to significant enrichment or impoverishment value in
transcription factor binding sites (TFBS) at 5% risk (Fisher’s test). Hatched squares indicate expected enrichment according to the expression level of
the corresponding transcription factor (TF). Right panel: for each transcription factor (rows), expression values (cells) extracted from our DMD/AGE
meta-clusters (columns) was reported. Red was applied to high level expression values, black to middle expression values and green to low
expression values. High p-values obtained from T-test are visualized with blue (DMD group) or pink AGE group. Transcription factors for which
enrichment values were significant in one hand and for which expression values were differential on the other hand were selected. C-. Fourteen
significantly over expressed Transcription factors with significant enrichment of TFBS in the promoters of genes in at least one of our meta-cluster
were identified. ELF1, IRF8, STAT1, STAT6 and XBP1 were associated with the meta-cluster DMD+; ETS1, IRF1 and NF1 with DMD+ AGE+; FOXC1, VDR
and MEIS1 with AGE+; PITX2 and RORA with DMD2; and ESRRA with DMD2 AGE2.
doi:10.1371/journal.pone.0026952.g005
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genes mainly involved proteins of the energy metabolism, up-
regulated genes encoded proteins linked to an inflammatory/
immune response, representing the largest class of transcripts that
display a large (2-fold or more) change in expression pattern with
aging. These finding thus suggests that as found in the DMD, a
cytokine-mediated inflammatory response also occurs in the
AGING muscle which could be involved in the atrophying
process.
Identifying Common deregulated pathways
We found that down regulation of genes in both conditions
(DMD2 AGED2) may be mediated by the orphan nuclear
estrogen-related receptor a (ESRRA), a recently discovered
regulator of mitochondrial biogenesis [42]. Bioinformatic analyses
revealed that it belongs to the mitochondrial co-expression module
in the mammalian skeletal muscle [43]. Moreover, contractile and
energy generation promoters also contain the ESRRA motif in co-
expression modules deduced from a wide range of degenerative
heart disease [44]. ESRRA was recently demonstrated to target a
common set of promoters involved in the uptake and production
of energy substrate across the mitochondrial membranes,
intracellular fuel sensing (Ca2+ handling and contractile work…)
[45]. Association of down-regulation of ESRRA to muscle fiber
loss in DMD and with AGE as a direct or a secondary
consequence still remains to be elucidated.
In DMD+ AGED+, overexpression of several genes is related
for the secondary response composed of the connective tissue
infiltration and extracellular matrix proliferation. Our analysis
identified three transcription factors –the avian v-ets erythroblas-
tosis virus E26 oncogene homolog 1 (EST1), the interferon
regulatory factor 1 (IRF1) and the neurofibromin1 (NF1)-related
to this response. They may coordinate gene changes in the
invading cells to regulate the immune response and/or the
extracellular matrix remodeling. Indeed, the proto-oncogene
ETS1 is involved in both normal and pathological functions and
is expressed in a variety of cells, including endothelial cells,
vascular smooth muscle cells and epithelial cells. It regulates the
expression of several angiogenic and extracellular matrix remod-
eling factors promoting an invasive phenotype [46]. The high
expression of ETS1 observed in our conditions could be correlated
to infiltrating activated T-cell [47]. Thus ETS1 would be a key
mediator of the extracellular-signal induced activation. IRF1 is a
multifunctional transcription factor acting downstream of the
JAK/STAT pathway, and notably involved in cell growth
regulation, inflammation, immune response and immune activa-
tion [48]. It belongs to the immune transcriptional module in the
muscle [43].
NF1 is a tumor suppressor protein encoded by the NF1 gene.
Mutations in the NF1 gene cause Neurofibromatosis 1 which is
mainly characterized by the development of multiple benign
tumors of nerves and skin. The musculoskeletal system is also often
affected (e.g. scoliosis and bowing of the lower legs). NF1 is
predominantly detected in neurons, nonmyelinating Schwann cells
and oligodendrocytes but is also expressed in skeletal muscle or
smooth muscle [49]. Indeed muscle-specific isoforms of NF1 have
been identified [50]. NF1 is required for the development and the
maintenance of the musculoskeletal system and could contribute to
the musculoskeletal problems in patients affected with neurofibro-
matosis type 1. As shown in our study, NF1 is involved in the
rearrangement of cytoskeletal components. Skeletal muscle from
mice with NF1 inactivation gene shows a dystrophic skeletal
muscle aspect with fibrosis and reduced number of muscle fibers
and altered differentiation of satellite cells [51].
Specific Gene signatures to DMD or AGED
Finally, our results show that in both situations, different causes
may lead to the same consequences as observed by common gene
signatures of both DMD and AGED muscle. However, according
to the other gene signatures observed in one of the two situations,
specific pathways also exist and will be the scope of next studies to
identify the precise role of transcription factors (e.g. ESRRA,
MYOG, and VDR) as we recently developed for other tissues [52].
For instance, while in the DMD muscle the lack of dystrophin is
clearly identified as the primary cause of muscle loss, in AGED the
process has not been elucidated yet. However, we found that genes
down-regulated only in the AGED muscle (DMD0 AGED2)
suggests a motor unit remodeling process as hypothetical primary
cause. Indeed, several evidences suggest that one principal
mechanism accounting for the age-related muscle mass loss could
be the age-related decline of peripheral nervous system. Motor
units and neuromuscular junction demonstrate anatomic and
physiological remodeling with age such as reduced total number,
relative increase of muscle fibers per motor unit, increase in pre-
synaptic nerve terminal branching associated with increased
quanta content [53]. The continual loss of fast motor neurons
would lead to a progressive process of myofiber denervation
associated with incomplete re-innervation by slow motor neurons
contributing to the ineluctable muscle atrophy with a denervation
rate probably exceeding the re-innervation rate in the elderly.
Indeed, remodeling of the neuromuscular junction precedes
sarcopenia related alterations in myofibers [54]. These findings
are now under new investigations to clarify the precise role of these
biomarkers - particularly the transcription factors- in the context of
muscle pathology.
To conclude, if the number of relevant studies related to muscle
continues to rapidly increase, efficient exploitation of these wide
data is frustrated by the lack of an integrated data mining platform
or other unifying bioinformatic resource. To facilitate the
integrative analysis of microarray data on muscle, it could be
thus useful to develop automatic tool relying on meta-analysis
approaches (coexpression, signature, fold change). This will allow
to focus on mechanisms involved in regulating the observed
phenotypic changes. Indeed, by exploring common regulatory
networks, we will identify key regulators of muscular tissue
remodeling.
Materials and Methods
In laboratory study
Patient samples. Written informed consents were collected
for all the patients involved in our study that was approved by the
ethical committee of the Nantes University Hospital (France).
Muscle tissue samples (paravertebral or fascia lata muscles) were
rendered anonymous before beginning the study (see Table 1 for a
complete description). They were from four male patients (ages:
11–13 years) undergoing orthopedic surgery. Patients were
diagnosed with DMD (DMD group) on the basis of clinical
examination, histological analysis and absence of dystrophin at the
immuno-fluorescence analysis. Four AGE samples were collected
in subjects (ages: 42–65 years; 1 male and 3 females) during
surgery for idiopathic scoliosis (AGE group). Reference skeletal
muscle samples (CONTROL group) were obtained from seven
subjects (ages: 14–30 years; 2 males and 5 females) undergoing
surgery for idiopathic scoliosis.
Microarray experiments and cluster analysis. Microarray
preparation and hybridization, expression data acquisition and
processing were described in Data S1. The transcriptome
experiment was performed using the Nantes’ Integrative Genomic
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previously published (see for details [36,55]). Data were normalized
and analyzed using the Micro-Array Data Suite of Computed
Analysis (MADSCAN) [56].
A total of 2,745 genes were found to be consistently expressed in
our experimental conditions. These gene expression profiles were
used to classify genes and biological samples using a hierarchical
clustering method with the Gene Cluster program. The input
matrix consisted of the log2-transformed median of the replicate
expression values for each gene. The clustering method employed
was an average linkage with the Pearson correlation coefficient as
a similarity metric. Results were displayed using the Java
Treeview. Our dataset has been deposited in the GEO database
(Series record GSE32720).
Real time RT-PCR. Quantitative RT-PCR (Taqman Gene
expression assays, Applied Biosystems) was used to assess the
reliability of the measures obtained from microarray experiments.
A set of 10 genes distributed along the entire range of gene
expression variation for DMD and AGE subjects was selected.
Helicase with zinc finger domain (HELZ) was taken as an internal
standard. PCR reactions were performed on the same samples that
those used for the microarray experiments. Three of the four
DMD and three of the four AGE subjects were compared
individually to the pool of seven control subjects (CONTROL).
Duplicate experiments were performed and each experiment
contained duplicate PCR reactions. Mean gene expression ratios
were calculated for each DMD and AGE subjects versus
CONTROL.
Statistical analysis. Differentially expressed genes (DEGs) in
DMD or AGE groups compared to control group were detected
using two statistical methods specifically adapted to microarray
data: SAM (Significance Analysis of Microarrays) and LIMMA
(Linear Models for MicroArray data). To minimize false positive
cases (false discovery rate, FDR), genes selected only by both
methods were admitted in the final list of DEGs (FDR,0.02;
p,0.01). A hierarchical clustering was also applied on clusters of
DEGs.
Orientated validation: data processing from independent
DMD and AGE public studies
Microarray datasets and related information on samples were
downloaded from GEO at the National Center for Biotechnology
Information (NCBI, Bethesda, MD). They include 6 series related
to DMD [GSE6011, GSE1007, GSE1004, GSE3307, GSE465,
GSE1764] and 6 series related to AGE [GSE1428, GSE10760,
GSE80, GSE8479 and GSE9676 gathering GSE362 and
GSE674]. All these data sets (raw, normalized and analyzed data)
can also be retrieved in the MADMuscle database (www.madtools.
org, [57]), a resource dedicated to the analysis of muscle
transcriptome data. Normalization: for each individual data set,
non-linear effects such as background or saturation were corrected
by LOWESS as previously described [15].
For each GEO platform (GPL), information on probe-sets was
gathered in the MADGene database (www.madtools.org) and
completed with related information collected from the NCBI
Entrez gene database and Unigene databases [58,59]. Based on
this annotation, genes found as differentially expressed in our study
were retrieved in each independent GEO dataset.
Each dataset was individually preprocessed applying a logarith-
mic transformation and a median centering on genes [60], so that
relative variations rather than absolute values were used for
interpretation. When multiple probes were found for a same gene,
only the probe with the smallest p-value (student’s T test) between
distinguished experimental groups (DMD vs CONTROL or AGE
vs CONTROL) was kept for further analyses [61]. The data were
merged into two independent meta-matrixes dedicated to DMD
and AGE effects respectively. In each meta-matrix, a Student’s T
test (p-value,0.01) was applied on each gene expression meta-
profile to identify significant variations between the studied groups.
Additionally, genes with sex biased expression values were
Table 1. Clinical features of the three groups of patients.
Name Sex Age Clinical Examination Muscle Treatment
DMD Group
DMD1 = 12 Armchair since 1 year, minor cognitive impairment Fascia lata tensor No
DMD2 = 11 Armchair since 2 years Fascia lata tensor No
DMD3 = 11 Armchair since 4 years Fascia lata tensor No
DMD4 = 13 Armchair since 2 years Paravertebral No
AGE Group
AGING1 = 42 Idiopathic scoliosis Paravertebral No
AGING2 R 65 Idiopathic scoliosis Paravertebral No
AGING3 R 59 Idiopathic scoliosis Paravertebral No
AGING4 R 47 Idiopathic scoliosis Paravertebral No
CONTROL Group
CONTROL1 R 30 Idiopathic scoliosis Paravertebral No
CONTROL2 R 19 Idiopathic scoliosis Paravertebral No
CONTROL3 = 14 Idiopathic scoliosis Paravertebral No
CONTROL4 R 16 Idiopathic scoliosis Paravertebral No
CONTROL5 R 27 Idiopathic scoliosis Paravertebral No
CONTROL6 R 16 Idiopathic scoliosis Paravertebral No
CONTROL7 = 18 Idiopathic scoliosis Paravertebral No
doi:10.1371/journal.pone.0026952.t001
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according to their validation status (over-expression, under-
expression or no change compared to CONTROL) and displayed
with Java Treeview.
Blind validation: data processing from a wide panel of
public studies
DMD/AGE isolated genes from previous Orientated Meta-
analysis were validated in terms of co-expression, fold-changes and
gene signatures exploring thousands of data expression in various
conditions (pathological or not) and species (including human).
Co-expression analysis. Reliable co-expression neighbors
of DMD/AGE genes were found across multiple independent
datasets using GEMMA on the basis of their expression profiles
correlation [62,63].
Differential expression analysis. We identified GEO
public datasets in which significant expression variations were
observed using GeneChaser server [64].
Gene signatures. For each DMD/AGED validated cluster
of DEG, the 50 significant overlapping gene sets were sought in a
large collection of transcriptional signatures using TBrowser [65].
Functional annotation and regulatory mechanism
identification
Functional annotation was performed using GoMiner tool and
gene ontology (GO) classification scheme. Regulatory mechanisms
were identified mining transcription factor (TF) data of MSignDB
from GSEA [66]. For each analyzed set of genes (DMD/AGE),
significant bias (over or under-representation) of GO identifiers
and transcription factor binding sites (TFBS) were calculated using
the Fisher’s exact test and the entire set of 2,745 expressed genes as
the reference population. Only bias with p-value lower than 0.05
were considered for interpretation.
Supporting Information
Figure S1 Functional analysis of the meta-clusters. The
functional analysis was performed for the three domains covered
by the ontology: ‘‘Cellular component’’ (left upper panel) which
corresponds to the parts of a cell or its extracellular environment;
‘‘molecular function’’ (left lower panel) which includes the
elemental activities of a gene product at the molecular level;
‘‘biological process’’ corresponding to the operations or sets of
molecular events with a defined beginning and end, pertinent to
the functioning of integrated living units (cells, tissues, organs, and
organisms). For each domain, Gene Ontology (GO in lines) profile
analysis of the meta-cluster (set of cross validated genes in columns)
is done. Bias of GO terms are depicted as colored squares (green
for under-represented terms, and red for over-represented terms),
with color intensity directly reflecting the range of the bias and
corresponding to the log10 of the GO enrichment scores. The
terms significantly (at 5% risk) associated with any of the 6 meta-
clusters are denoted by a white star.
(TIF)
Table S1 Genes differentially expressed in DMD and
AGING patients. Part 1: List of all the genes noted on GO
biological process and differentially expressed in DMD and
AGING patients. Part2: List of the Immune/Defense/Inflamma-
tion related genes differentially expressed in DMD and AGING
patients.
(XLS)
Table S2 Examples of studies identified as having
similar gene over-expression as observed in DMD
muscle.
(XLS)
Table S3 The 3588 genes spotted on the microarrays.
(XLS)
Data S1 Methods.
(PDF)
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